Current Month
Article Features
  Breast Cancer Screening Found Effective in Men at High Risk for the Disease
Exercise Prior to Breast Cancer Associated with Lower Risk for Heart Disease
Fewer Lymph Node Operations for Breast Cancer Patients with New Prediction Models
Mammography Unlikely to Benefit Older Women with Chronic Illnesses
New Blood Test Capable of Detecting Multiple Types of Cancer
Obesity and Psychosocial Well-Being Among Patients with Cancer
Only a Third of Women Take Up All Offered Cancer Screenings
Preclinical Study Reveals the Impact of Age on Immunotherapy Treatment for Breast Cancer
Scientists Discover New Breakthrough in Cancer Hair Loss Treatment
Simple Lifestyle Modifications Key to Preventing Large Percentage of Breast Cancer Cases
Study Finds Onion and Garlic Consumption May Reduce Breast Cancer Risk
Study Supports Germline Testing for All Metastatic Breast Cancer Patients
Survival in Women, Men Diagnosed with Breast Cancer
TAILORx: New Data on Cohort with Recurrence Score 26-100 Shows 93% Cancer-Free Rate at 5 Years
Targeted Therapy Drug Helps Women with Aggressive Breast Cancer Live Longer
Ultrasound Yields Similar Cancer Detection Rates After Digital Mammography, Tomosynthesis
Whole Genome Sequencing Could Enable Personalized Cancer Treatment
Women Equally Satisfied with Cosmetic Results of Partial, Whole Breast Radiation after Lumpectomy


TAILORx: New Data on Cohort with Recurrence Score 26-100 Shows 93% Cancer-Free Rate at 5 Years

A new analysis from TAILORx, the largest ever breast cancer treatment trial, was published in the journal JAMA Oncology. It reveals the clinical outcomes with chemotherapy in a subset of 1,389 women with a high Recurrence Score (RS) of 26-100. The outcomes are similar to the B20 trial (Paik et al, JCO, 2006). The new data shows that the estimated rate of freedom from recurrence of breast cancer at a distant site was 93% at five years, an outcome much better than expected with endocrine therapy alone. The results were featured at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona.

This finding adds to the limited data on outcomes of patients with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy regimens plus hormone therapy. It adds to the evidence base supporting the use of the Recurrence Score, a 21-tumor gene expression assay, to guide the use of adjuvant chemotherapy in early breast cancer.

TAILORx was designed and conducted by the ECOG-ACRIN Cancer Research Group with primary funding from the National Cancer Institute, part of the National Institutes of Health.

"The initial results of TAILORx gave clinicians high-quality data to inform personalized treatment recommendations for women," said lead author Joseph A. Sparano, M.D., associate director for clinical research at the Albert Einstein Cancer Center and Montefiore Health System in New York, and vice chair of the ECOG-ACRIN Cancer Research Group. "This new analysis provides the largest data set on outcomes in patients with early breast cancer and high Recurrence Score results. It confirms the importance of using the test to identify the minority of patients who will receive a significant benefit from adding adjuvant chemotherapy to endocrine therapy."

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner